-
2023-507132-21-00
10
2021-05-11
Early Parkinson's disease
-
2022-500237-92-00
5
2021-04-23
Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
-
2023-507274-40-00
3
2021-04-22
Myelofibrosis
-
2023-507961-24-00
5
2021-04-19
High-Risk HER2-Positive Breast Cancer
-
2023-506413-22-00
5
2021-03-31
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
-
2023-507418-28-00
4
2021-03-15
Solid tumors
-
2023-507695-52-00
5
2021-03-05
Mantle cell lymphoma
-
2023-509516-28-00
4
2021-02-22
Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III col
-
2022-503072-84-00
5
2021-02-13
stage IIIa cardiac AL amyloidosis
-
2022-503073-11-00
5
2021-02-13
Stage IIIb cardiac AL amyloidosis
-
2024-513730-38-00
5
2021-01-13
Resectable Non-small cell lung cancer
-
2023-503439-16-00
9
2020-12-29
Multiple Myeloma
-
2023-507263-19-00
5
2020-12-23
Advanced Non-Small Cell Lung Cancer
-
2023-503384-41-00
5
2020-12-22
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
-
2024-512575-12-00
9
2020-11-25
ADVANCED-STAGE, RELAPSED/REFRACTORY SOLID TUMORS
-
2023-509358-72-00
5
2020-11-23
Diffuse large B-cell lymphoma
-
2023-505852-23-00
5
2020-11-12
High risk recurrent prostate cancer previously treated with radical pr
-
2023-508281-15-00
1
2020-11-10
Locally Advanced or Metastatic Solid Tumors
-
2023-510390-33-00
5
2020-10-23
HER2-negative breast cancer patients with high relapse risk after
stan
-
2024-514404-13-00
5
2020-10-01
Atopic Dermatitis
-
2023-506877-37-00
5
2020-09-28
Relapsed/Refractory Multiple Myeloma
-
2024-513422-38-00
5
2020-09-28
Newly diagnosed multiple myeloma
-
2023-505812-39-00
5
2020-08-28
HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PI
-
2023-503421-19-00
5
2020-08-26
Urothelial cancer